That’s an important question because Indigo ASCENT™ isn't just a standalone improvement; it is the capstone of a deliberate, multi-year strategy to modernize our entire lab workflow. Our approach wasn't to automate a single piece of the puzzle, but to systematically transform the process from end to end.
We viewed our non-negative testing workflow in 3 distinct stages and tackled them sequentially:
1. Automating the front end: Eliminating the bottleneck
We started at the beginning: sample preparation. This was historically our most manual and time-consuming step. By investing in automated aliquoting, we removed that critical bottleneck. This immediately increased our capacity and consistency, setting the stage for further automation downstream.
2. Modernizing the core: A strategic platform shift
With the front-end streamlined, we focused on the analytical engine. We executed a strategic platform shift to a new, standardized LC-MS/MS system. This was about more than just newer, faster instruments; it was about creating a unified, highly efficient core that simplified our processes, training, and maintenance.
3. Integrating the back end: The final mile with Indigo ASCENT™
This is where Indigo ASCENT™ fits in, and it's the crucial final piece. It automates data analysis and review, effectively connecting our automated front end and modernized core into a single, seamless, "walk away" process.
The result: A world-class, automated workflow
By pursuing this phased strategy, we have done more than just implement new technology; we have fundamentally re-engineered our workflow. By the second half of 2026, we project that over 85% of our non-negative testing will be fully automated, from presumptive positive to final report. This journey has not only dramatically improved our efficiency and turnaround times but has also created a powerful blueprint for future modernization across the entire laboratory.